Suchergebnisse - "Doubre, Hélène"

PubPharm (45)

1

Plasma tissue factor activity in lung cancer patients predicts venous thromboembolism and poor overall survival

enthalten in: Research and practice in thrombosis and haemostasis | 2024

von Doubre, H. | Monnet, I. | Azarian, R. | +8

2

Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer

enthalten in: Journal of cancer research and clinical oncology | 2023

von Doubre, H. | Greillier, L. | Justeau, G. | +14

3

Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)

enthalten in: Targeted oncology | 2023

von Dhamelincourt, E. | Descourt, R. | Rousseau-Bussac, G. | +15

4

Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)

enthalten in: Targeted oncology | 2023

von Dhamelincourt, E. | Descourt, R. | Rousseau-Bussac, G. | +15

5

Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study)

enthalten in: Journal of immunotherapy (Hagerstown, Md. : 1997) | 2023

von Decroisette, C. | Greillier, L. | Curcio, H. | +16

6

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer : GFPC 03-18 Study

enthalten in: Targeted oncology | 2023

von Babey, H. | Jamme, P. | Curcio, H. | +12

7

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study

enthalten in: Targeted oncology | 2023

von Babey, H. | Jamme, P. | Curcio, H. | +12

8

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study

enthalten in: Targeted oncology | 2023

von Babey, H. | Jamme, P. | Curcio, H. | +12

9

Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies : A multicentre phase II open-label non-randomised study GFPC 06-2018

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Bylicki, O. | Tomasini, P. | Radj, G. | +20

10

First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world : impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)

enthalten in: Cancer immunology, immunotherapy : CII | 2023

von Descourt, R. | Greillier, L. | Perol, M. | +17

1
2
3
4
5
Nächster »
[5]